RSV vaccine makers vying for market share in second year of shots

Pfizer's (PFE.N), GSK's (GSK.L), and Moderna's (MRNA.O) competition for arms for their new respiratory syncytial virus (RSV) vaccines is on Wall Street's watch list for when the companies report earnings later this week.